Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma

Y. Fujita, T. Nakamura, T. Aomori, H. Nishiba, T. Shinozaki, T. Yanagawa, K. Takagishi, H. Watanabe, Y. Okada, K. Nakamura, R. Horiuchi, Koujirou Yamamoto

研究成果: Article

5 引用 (Scopus)

抜粋

Individualization of high-dose methotrexate (MTX) dosing is important to achieve therapeutic levels (700-1,000 μM) for osteosarcoma. Therefore we developed a pharmacokinetically (PK) individualized dosage regimen to maintain MTX concentrations of 700 μM (1 h bolus followed by 5 h maintenance infusion) and evaluated its safety and efficacy. Loading and maintenance doses were calculated by the PK parameters based on 2-compartment model analysis. Thirty-two courses of chemotherapy were performed in 9 patients with osteosarcoma. The maximum concentrations during maintenance infusion in 31 courses (97%) were above 700 μM. Only 1 patient developed severe hepatotoxicity as adverse effect. Total body clearance of MTX decreased in 4 patients when weekly MTX chemotherapy was performed for 3 consecutive weeks. Although the clearance was changed, the average MTX concentrations were maintained at about 700 μM by the PK individualization. The 5-year survival rate was 77.8% (7 of 9 patients), and all of them have survived for more than 9 years. This PK individualization is safe and useful for tailoring high-dose MTX therapy to achieve therapeutic levels.

元の言語English
ページ(範囲)186-190
ページ数5
ジャーナルJournal of Chemotherapy
22
発行部数3
DOI
出版物ステータスPublished - 2010 6
外部発表Yes

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

フィンガープリント Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用

    Fujita, Y., Nakamura, T., Aomori, T., Nishiba, H., Shinozaki, T., Yanagawa, T., Takagishi, K., Watanabe, H., Okada, Y., Nakamura, K., Horiuchi, R., & Yamamoto, K. (2010). Pharmacokinetic individualization of high-dose methotrexate chemotherapy for the treatment of localized osteosarcoma. Journal of Chemotherapy, 22(3), 186-190. https://doi.org/10.1179/joc.2010.22.3.186